Navigation Links
A new discovery about Acetaminophen

According to a new enzyme which is discovered, may interpret the reasons for acetaminophen acting differently from other painkillers. //Acetaminophen (paracetamol in the UK) is known to relieve pain and fever, but not inflammation. Whereas aspirin and ibuprofen tackle inflammation too and are known as non-steroidal anti-inflammatory agents (NSAIDs). These drugs are known to block two enzymes - cyclo-oxygenase (COX)-1 and COX-2. It is COX-2 which generates pain signals, but COX-1 helps produce the protective mucus that lines the stomach. Inhibition of COX-1 leads to the sometimes serious side effects of NSAIDs like stomach irritation and bleeding.

Researchers at Brigham University in the US have now discovered a new COX enzyme, COX-3, which appears to be the target of acetaminophen. This explains why the drug is a good painkiller, even though it has very little effect on COX-1 or COX-2. The study may help scientists discover even more useful painkillers in the future. Acetaminophen is useful for people who can't take standard NSAIDs and is, in general, very safe.


'"/>




Page: 1

Related medicine news :

1. Latest discovery on Autism
2. Bacterial discovery may help CF patients
3. A new discovery about Acetaminophen
4. Resistant tumors could be treated with the discovery of a new molecule within cancer cells
5. Treatment for cholesterol-related illnesses likely with the discovery of receptor in mice
6. Ways to counter radiation effects with new molecule discovery
7. Canada stunned as mad cow discovery leads to beef ban
8. Mouth Infection better handled with new discovery
9. New discovery made about the Nipah Virus
10. Ranbaxy opens Drug discovery centre in Gurgaon
11. Recently discovered deep-sea reefs catch the attention of the drug discovery team
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: new discovery about Acetaminophen

(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
(Date:12/24/2014)... St. Louis, MO (PRWEB) December 24, 2014 ... Onder Law Firm announce an update to their website, ... information explains the difference between talcum powder class action ... provide weekly talcum powder and ovarian cancer updates at ... , “Talcum powder lawsuits for ovarian cancer claims are ...
(Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... steady diet of fast food might hurt your child in ... ate fast food in fifth grade lagged behind by eighth ... more than 8,500 U.S. students. "The largest effects were ... food," said study leader Kelly Purtell, assistant professor of human ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Though most patients ... medication and therapy, between 10 percent to 20 percent ... to standard care, experts say. However, patients with ... form of a type of brain surgery that disables ... The challenge: to distinguish between patients most likely to ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... noticeable toll and can present in the form of ... folds with the start of the marionette line or ... topical treatments and diligent skincare, but as the deep ... and Restylane are all synthetic fillers that can be ...
Breaking Medicine News(10 mins):Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2
... Continued year over year growth driven by Loestrin 24 and Taclonex; ... updates full year 2007 financial guidance, ... ) today announced its results for the quarter ended,September 30, 2007. ... increase of 16.3%, over the prior year quarter. The,primary drivers of ...
... announced today that the U.S. Food and Drug ... adjunct to diet to slow,the progression of atherosclerosis ... CRESTOR an important differentiator from,competitors in the cholesterol-lowering ... share what we,ve learned in clinical,trials -- that ...
... EXTON, Pa. and SAN DIEGO, Nov. 9 ,RS&A, ... of oncology equipment sales and service, announced today ... Radiology Oncology Systems, Inc.,(ROS), an oncology and diagnostic ... a US provider of oncology equipment service,and distributor ...
... 8 State,Compensation Insurance Fund is presenting a ... Fund,s Employer Education Series, featuring its own,innovative and ... seminar entitled "Watch Your Back",introduces an educational and ... the very people they are trying to protect ...
... following release is,being issued by the Department of ... is the largest federal provider of direct assistance ... and case,management, employment, rehabilitation, transitional residential care,therapeutic work ... has been a 22 percent reduction in the ...
... Warns of Critical and Fatal Implications of ... the Diagnosis of Carbon Monoxide Poisoning, IRVINE, Calif., ... Read-Through Motion and Low Perfusion pulse,oximetry, today announced the ... all its members advocating carbon monoxide,screenings for patients presenting ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 2Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 3Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 4Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3Health News:Homeless Vets - VA Sets the Record Straight 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 3
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... SPRINT-1 study presented at AASLD annual meeting, ... patients and those,who failed prior treatment, SAN ... ) today reported that a planned interim analysis ... investigational oral hepatitis C,protease inhibitor, in combination with ...
... COPENHAGEN, Denmark, October 31 , - DoctorConsult ... That Improve Clinician Decision Making and Health Care ... workflow and more than a,century of experience as ... to provide interactive clinical reference and clinical decision,support ...
Cached Medicine Technology:Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: